Find Academic Supervisors

Ejung Moon is a Group Leader in Radiation Biology and the Tumour Microenvironment at the Department of Oncology, University of Oxford's Medical Sciences Division. Her research focuses on hypoxia-driven tumor progression and radiation response mechanisms. Education: PhD in Pharmacology and Cancer Biology from Duke University Training: Postdoctoral work with Amato Giaccia at Stanford University Research Interests: Elucidating how hypoxia-induced MAFF protein regulates tumor cell invasion, metastasis, and radiation resistance through antioxidant response pathways. Current work explores MAFF dimerization dynamics and metabolic reprogramming in hypoxic tumors. Scientific Contributions: Identified MAFF's role in radiation-induced antioxidant gene regulation (2021, Nature Communications ). Recent studies investigate iron metabolism's impact on FLASH radiotherapy effects. Scientific Awards: Breast Cancer Research Program (BCRP) predoctoral fellowship Laboratory & Collaborations: Moon Lab collaborates with Oxford Cancer and NHS Cancer and Haematology Centre. Key partnerships include Stanford University's radiobiology research groups.

• Radiation Biology
• Tumour Microenvironment
• Transcriptional Regulation
• +3 more

Deborah Frances Smith is a Professor affiliated with the Centre for Immunology and Infection. She has held former roles including Head Of Department, Biology Pro-Vice-Chancellor for Research, and Special Adviser to the Vice Chancellor in the Vice Chancellor's Office. She is also associated with CNAP (Cancer and Neuroscience Academic Programme) and the Jack Birch Unit. Her research focuses on leishmaniasis, parasite biology, and drug/vaccine development. Key projects include leading the 'C2D2 research 1a & 2b' (2012–2012) to establish sandfly colonies for leishmaniasis studies and co-investigating an integrated crystallization facility (2013–2018). She secured the Wolfson Research merit Award (2009–2010) from the Royal Society. Her work spans academic leadership, collaborative research, and translational medicine targeting neglected tropical diseases.

• Leishmaniasis
• Immunology
• Parasitology
• +3 more

Dr. Samira Lakhal-Littleton is an Associate Professor of Cell Physiology and MRC Senior Non-Clinical Research Fellow at the University of Oxford, affiliated with the Department of Physiology, Anatomy and Genetics and Brasenose College. Her research focuses on iron homeostasis, systems biology, and oxygen sensing mechanisms in cardiovascular and systemic physiology. Education: BSc in Human Genetics (University College London), DPhil in Molecular Medicine (University of Oxford) Her work bridges cell physiology and translational medicine, with key discoveries on hypoxia-inducible factors (HIFs), iron regulatory genes TMPRSS6 and GDF15 , and the role of hepcidin in altitude adaptation and chronic diseases. She utilizes tissue-specific animal models to study iron regulation in heart, kidney, placenta, and vasculature. Recent publications highlight her contributions to understanding: FLASH radiotherapy effects linked to iron-dependent lipid peroxidation Clinical implications of myocardial iron dynamics in heart failure Hepcidin's role in vascular protection and placental iron transfer Biomarker development for predictive iron deficiency diagnostics Scientific Leadership: British Heart Foundation Intermediate Fellowship (2012) MRC Senior Fellowship (2020) BioIron Society Board Member (2019) She collaborates with clinical teams on translational projects and serves as a Tutorial Fellow in Medicine at Brasenose College, mentoring students in physiological sciences.

• Iron Homeostasis
• Cell Physiology
• Systems Biology
• +4 more

Karen Piper Hanley is Professor of Molecular Medicine and Head of Division in the Division of Diabetes, Endocrinology & Gastroenterology at the University of Manchester. She serves as the fibrosis lead in the Wellcome Trust Centre for Cell-Matrix Research and previously served as Director of Core Research Technologies (2019-2022). She is also an editorial board member for Scientific Reports. Her research focuses on fibrosis (scarring) mechanisms across multiple organs, particularly liver, kidney, and lung fibrosis. Her lab investigates the cellular and molecular basis of fibrotic disease, with emphasis on how pathological scar components are produced and how they signal to surrounding cells. Key areas include the role of SOX9 transcription factor, integrin beta-1 signaling, Group 1 PAKs, and YAP1 in fibrosis progression. Her recent publications reveal trends toward increased clinical translation of fibrosis research, with studies on health inequalities in liver cancer care, post-COVID diabetes incidence, and innovative approaches to liver disease detection. Her work increasingly integrates spatial transcriptomics and advanced omics technologies to understand cellular transitions in liver disease. Career-track postdoctoral fellowship from the University of Southampton (2006) As senior postgraduate tutor, she has mentored numerous PhD students who have presented at key conferences and authored high-quality manuscripts. All her PhD students have submitted and been awarded their degrees within 4 years. She has successfully guided previous Academic Clinical Fellows to win MRC clinical training fellowships. Her teaching extends to undergraduate Personal & Professional Development and supervision of MRes and BSc students, many of whom have achieved first-class degrees and prestigious awards. Her lab maintains active collaborations with Professor Neil Hanley's group on human development, stem cells, and regenerative medicine, bridging developmental biology with fibrosis research to understand why regeneration is impaired in chronic diseases.

• Fibrosis Research
• Liver Fibrosis
• Kidney Fibrosis
• +9 more

James Briscoe is a Senior Group Leader at The Francis Crick Institute in London, where he leads a research group focused on developmental biology and morphogen signaling. He previously held positions at the Medical Research Council's National Institute for Medical Research, which later became part of the Francis Crick Institute. Education: BSc in Microbiology and Virology from the University of Warwick, UK PhD from Imperial Cancer Research Fund/King's College London Postdoctoral training at Columbia University with Thomas Jessell Dr. Briscoe's research focuses on the molecular and cellular mechanisms of graded signaling by morphogens and the role of transcriptional networks in cell fate specification. His laboratory employs a range of experimental and computational techniques using model systems including mouse and chick embryos and embryonic stem cells. His work has significant implications for understanding developmental processes and their relationship to disease. His recent publications demonstrate a continued focus on morphogen gradients, neural tube development, and computational approaches to understanding cell fate decisions. His research increasingly integrates single-cell technologies and computational modeling to unravel the complexities of developmental patterning. Scientific Awards and Honors: EMBO Young Investigator (2001) EMBO Gold Medal (2008) Elected to EMBO (2009) Fellow of the Academy of Medical Sciences (2019) Fellow of the Royal Society (2019) As Editor-in-Chief of the journal Development since 2018, Dr. Briscoe plays a significant role in shaping the field of developmental biology. His leadership extends to mentoring researchers and contributing to scientific policy discussions, as evidenced by his recent publication 'Science under siege: protecting scientific progress in turbulent times.' Dr. Briscoe's laboratory at the Crick Institute is well-equipped with access to advanced facilities including light microscopy, flow cytometry, genomics, and computational resources, enabling a multidisciplinary approach to developmental biology questions.

• Developmental Biology
• Molecular Signaling
• Transcriptional Networks
• +4 more

Calliope Dendrou is an Associate Professor in Clinical Pathology and Inflammation at the Kennedy Institute of Rheumatology (KIR), University of Oxford, leading the Immune Disease Multiomics Laboratory. She previously held a Wellcome & Royal Society Sir Henry Dale Fellowship at the University of Oxford’s Centre for Human Genetics before joining KIR in 2023. Her research focuses on immune disease mechanisms using multiomics approaches, including genomic profiling to identify therapeutic targets across tissues and immune-mediated diseases. She co-leads large-scale projects like the Oxford-J&J Cartography Consortium and the Chan Zuckerberg Initiative’s LEGACY Network, and teaches on the MSc in Genomic Medicine program. Educational Background: BSc (Biology, Imperial College London, 2005; Forbes Memorial Medal Winner); PhD in Infection & Immunity (University of Cambridge, 2010). Postdoctoral training at the Weatherall Institute of Molecular Medicine under Prof. Lars Fugger. Research interests include immunogenetics, cytokine signaling pathways, drug repositioning, and cross-disease pathophysiology. Her work integrates single-cell and spatial transcriptomics to dissect immune-cell interactions in diseases like rheumatoid arthritis, inflammatory bowel disease, and celiac disease. Recent articles highlight her contributions to understanding vaccine adjuvant responses, Th17 cell roles in spondyloarthritis, and immune-epithelial networks in celiac disease. Collaborations emphasize multi-omic data analysis (e.g., Panpipes pipeline) and translational studies toward precision medicine. Awards: Forbes Memorial Medal (BSc), Wellcome & Royal Society Sir Henry Dale Fellowship. Leadership roles include Equality, Diversity, and Inclusion Champion and 'Single-Cell & Spatial Omics for Precision Medicine' Module Lead. Lab & Teams: Immune Disease Multiomics Lab at KIR. Active in collaborative initiatives such as the LEGACY Network, focusing on large-scale immune profiling in ancestrally diverse populations.

• Immunology
• Genomics
• Multiomics Analysis
• +3 more

Professor David Grainger is a faculty member at the University of Birmingham's School of Biosciences, specializing in Molecular Microbiology. He leads the Grainger Lab, focusing on bacterial chromosome biology, pathogenicity, and antibiotic resistance. His research integrates high-throughput techniques and single-molecule analysis to study gene regulation and bacterial pathogenesis. Education: PhD (2004), PGCE (2000), BSc (1999) in Biochemistry from the University of Birmingham. Affiliations: Part of the Institute of Microbiology and Infection (IMI), collaborating with experts in genomics, proteomics, and structural biology. Research Interests: Deciphering chromosome biology of pathogenic bacteria, including transcriptional regulation, toxin production control, and antibiotic resistance pathways. Utilizes cutting-edge methods like Hi-C for 3D chromatin analysis and single-molecule microscopy. Recent Articles: Focused on transposon capture mechanisms, bacterial promoter diversity, and quorum sensing signaling. Highlights include studies on Salmonella regulons and Vibrio cholerae biofilm suppression. Awards: Wellcome Trust Career Development Fellowship (2008), Runner-up in 'Science Snaps' competition for scientific communication. Grants: Career Development Fellowship-funded establishment of his research group at the University of Warwick (2008). Labs/Teams: Grainger Lab at the University of Birmingham, part of the IMI network. Engages in public science outreach via Twitter and lab website.

• Bacterial Chromosome Biology
• Pathogenicity
• Antibiotic Resistance Mechanisms
• +3 more

Jonny Kohl is a Group Leader at the Francis Crick Institute , where he established the State-dependent Neural Processing Laboratory in 2019. His work bridges neural circuits and internal physiological states (e.g., hunger, pregnancy) to decode instinctive behaviors like parenting and aggression in mice. PhD: MRC Laboratory of Molecular Biology, Cambridge (2013) Postdoc: Harvard University (2014–2019) with support from EMBO, HFSP, and Wellcome Trust fellowships Research Interests : Kohl investigates how hormonal and metabolic states dynamically rewire neural circuits to drive adaptive behaviors. His lab combines circuit neuroscience , molecular biology , and behavioral profiling to study: State-dependent neural processing in parental behavior Chemosensory dominance hierarchies in mice Plasticity mechanisms in aggression circuits Development of ultrafast tissue labeling and cryoanesthesia tools Scientific Trends : His recent publications highlight hormone-mediated synaptic remodeling (2023), cost-effective lab tools (2023), and brain-wide activity mapping (2016). Collaborative work spans computational biology , metabolism , and imaging disciplines. Honors: NARSAD Young Investigator Award (2019), ERC Starting Grant (2019), Wellcome Trust Discovery Award (2025) Grants: BBSRC Research Grant (2025), BBSRC Pioneer Grant (2023) His lab mentors PhD and MSc students and has developed open-source neuroscience tools (e.g., cryoanesthesia device, 2023). Kohl's research has been featured in Nature , Science , and Cell .

• Neuroscience
• Neural Circuits
• Behavioral Biology
• +4 more

Silvia Santos is a Group Leader at the Francis Crick Institute, leading the Quantitative Stem Cell Biology Lab since January 2018. Her research focuses on understanding cell decision-making during transitions, specifically cell division and differentiation in early development using human embryonic stem cells. She combines experimental techniques with theoretical approaches, including advanced microscopy, genomics, and computational modeling. Education and Career: PhD in Molecular and Cell Biology from EMBL-Heidelberg (2008), followed by postdoctoral training at Stanford University (2009-2014). She held an MRC Career Development Award at Imperial College London (2014-2017) before joining the Crick. Her work emphasizes interdisciplinary methods to study cellular processes in health and disease. Research Interests: Spatial-temporal control in cell decisions, stem cell differentiation, cell cycle regulation, and modeling embryonic development. She advocates for women in science and mentorship programs for early-career researchers. Key Achievements: Recipient of Marie Curie E-Star, EMBO, and HFSP fellowships. Recognized with the BioModels’ Model of the Year 2023 for contributions to systems biology. Her lab develops models like gastruloids to study embryonic development. Grants and Mentorship: Supported by MRC and other grants. Committed to fostering excellence in training and mentorship, previously chairing mentorship initiatives at Imperial College London. Labs and Teams: Quantitative Stem Cell Biology Lab at the Crick, collaborating with interdisciplinary teams on projects involving proteomics, genomics, and high-throughput screening.

• Developmental Biology
• Cell Biology
• Cell Cycle & Chromosomes
• +3 more

Christopher Buckley is the Kennedy Professor of Translational Rheumatology and Director of Clinical Research at the Kennedy Institute of Rheumatology, University of Oxford. He holds concurrent roles as Director of NIHR Infrastructure for Birmingham Health Partners. His research focuses on fibroblast biology in rheumatoid arthritis (RA), stromal cell interactions, and translational medicine approaches to stratified therapy. He leads the Arthritis Therapy Acceleration Programme (A-TAP), advancing precision medicine strategies for immune-mediated inflammatory diseases. Educations: BSc Biochemistry, University of Oxford (1985) MBBS Medicine, Royal Free Hospital, London (1990) DPhil in Molecular Medicine (Wellcome Trust Fellowship) under Prof. John Bell (Oxford) Research Interests: Pathogenic fibroblast subpopulations in RA and systemic sclerosis Tissue-resident memory T cells in chronic inflammation Spatial transcriptomics of synovial and tendon tissues Pro-resolving fibroblast networks during inflammation resolution Development of biomarkers for disease flare/remission Awards & Leadership: MRC Senior Clinical Fellowship (2001) Arthritis Research UK Professorship (2002) Director, Birmingham NIHR Clinical Research Facility (2012-2017) Key Projects: Leading A-TAP's stratified pathology approach for drug development Investigating Wnt signaling in stromal inflammation Developing cellular atlases of joints using spatial transcriptomics

• Rheumatology
• Inflammatory Diseases
• Fibroblast Biology
• +3 more

Dr. Gabriele Schweikert is a Senior Lecturer and Principal Investigator with a joint appointment between the Division of Computational Biology in the School of Life Sciences at University of Dundee and Cyber Valley in Tuebingen. Her research focuses on applying machine learning techniques to understand epigenetic mechanisms and molecular processes in living cells. Dr. Schweikert completed her PhD at the Max Planck Institute Tuebingen working with Schoelkopf, Weigel, and Raetsch labs on machine learning for computational gene finding. She subsequently joined Adrian Bird's lab at the Wellcome Trust Center for Cell Biology in Edinburgh, a pioneer in epigenomic research. Prior to her current position, she held prestigious Marie Curie and EMBO Fellowships at the School of Informatics, University of Edinburgh. Her research interests center on using machine learning to decode epigenetic mechanisms that determine cellular identity and function. She investigates how cells with identical DNA can differentiate into specialized cell types through epigenetic regulation, with particular focus on applications in understanding tumorigenesis where epigenetic machinery malfunctions. Her work combines high-throughput epigenomic data with advanced computational approaches to address complex biological questions. Analysis of her recent publications reveals a strong focus on epigenomic data analysis, machine learning applications in biology, and computational approaches to understanding gene regulation. Her work spans from fundamental epigenetic mechanisms to practical applications in disease research, with growing emphasis on individual-specific epigenomic analysis and explainable AI in biomedical contexts. UKRI Future Leaders Fellowship (2020, £1.6 million) Marie Curie Fellowship EMBO Fellowship Dr. Schweikert actively supervises PhD students and has received significant research funding for projects including 'Machine Learning Methods to Re-Annotate Histone Modifications,' 'Unlocking The Alternative Splicing Code,' and 'GPU-Based Machine Learning System For Fundamental Biological Research.' She is involved in multiple interdisciplinary collaborations and frequently presents her work at major conferences including ELLIS Health program retreat, Epigenetics Meetings, and RECOMB workshops. She maintains active research laboratories in both Dundee and Tuebingen, fostering international collaboration between computational biologists, machine learning experts, and experimental biologists to advance our understanding of epigenetic regulation in health and disease.

• Computational Biology
• Machine Learning
• Epigenetics
• +6 more

Dr. Megan Bergkessel is a Research Professor in Molecular Microbiology at the University of Dundee's School of Life Sciences. Her research focuses on understanding how bacteria like Pseudomonas aeruginosa regulate activities during growth arrest, particularly in resource-limited environments. This work addresses antibiotic tolerance mechanisms critical to chronic infections. Principal Investigator leading studies on non-growing bacterial physiology Recipient of a £900k UKRI Future Leaders Fellowship (2020) Expertise in antimicrobial resistance and microbial stress responses Current research explores regulatory pathways enabling protein synthesis in non-growing states, with implications for developing novel infection treatments. Supervises PhD projects investigating two-component signaling systems and environmental sensing in P. aeruginosa. Recognized for teaching excellence in Biological and Biomedical Sciences programs. PhD opportunities: Adaptive antimicrobial resistance mechanisms and environmental sensing roles Media commentary available via Corporate Communications

• Molecular Microbiology
• Antimicrobial Resistance
• Bacterial Physiology
• +3 more

Darryl Overby is a Professor of Mechanobiology in the Department of Bioengineering at Imperial College London's Faculty of Engineering. His academic affiliations include the CRUK Convergence Science Centre, Cancer Technology Network, and multiple interdisciplinary networks focused on ocular biomechanics, vascular science, and regenerative medicine. He holds an Orcid identifier (0000-0001-9894-7515) and was previously affiliated with Tulane University and Harvard Medical School. Education: Ph.D. in Mechanical Engineering (2002) from MIT under Prof. Roger Kamm, followed by postdoctoral research at Harvard Medical School under Prof. Donald Ingber. His work focuses on cellular biomechanics, mechanotransduction, and the role of mechanical forces in intraocular pressure regulation and glaucoma pathophysiology. Research interests span mechanobiology of Schlemm’s canal endothelial cells, nitric oxide signaling in ocular tissues, and development of organ-on-chip models for studying aqueous humor outflow dynamics. His lab explores how mechanical signals drive transcellular pore formation and how these mechanisms fail in glaucomatous conditions. Key contributions include consensus guidelines for Brillouin microscopy measurements, ex vivo perfusion studies, and the role of TRPV4 channels in mechanosensing. His work integrates engineering techniques with clinical ophthalmology to advance therapies targeting glaucoma and ocular hypertension. Professional activities include leadership roles in the Ocular Biomechanics Network and Wound Healing and Regeneration Network. His research has led to patents for devices enhancing aqueous humor drainage and RNAi-based therapies.

• Mechanobiology
• Ophthalmology
• Biomedical Engineering
• +4 more

Dr. Thomas A. Hughes is an Associate Professor of Cancer Biology at the University of Leeds and Professor of Biosciences at York St John University. As a Group Leader at the Leeds Institute of Medical Research, he focuses on gene regulation, tumour microenvironment, and nanomedicine approaches to improve cancer outcomes. Specializes in breast cancer, colorectal cancer, and rare diseases Develops therapeutic strategies using microRNAs and biomarkers Collaborates with clinicians, engineers, and chemists for translational research His research integrates molecular pathology with clinical data through partnerships with Leeds NHS Trusts, aiming to identify novel biomarkers and targets for therapy. Recent work emphasizes cholesterol metabolism, oxysterol signaling, and nanomedicine-based drug delivery systems. Key contributions include: Over 80 peer-reviewed publications in cancer biology and molecular therapeutics Leadership in MSc programs in Molecular Medicine and Cancer Biology and Therapy Extensive experience in grant review, editorial work, and doctoral supervision Scientific awards include Fellowship of the Higher Education Academy. His lab has mentored 26 doctoral students and numerous alumni in academia, clinical practice, and industry.

• Cancer Biology
• Gene Regulation
• Breast Cancer
• +6 more

Professor Colin Semple is a leading researcher at the University of Edinburgh's Institute of Genetics and Cancer (IGC), where he serves as Group Leader and Head of Bioinformatics. His work is conducted within the MRC Human Genetics Unit, focusing on computational genomics and the analysis of structural mutations in both germline and cancer contexts. Professor Semple's research investigates the origins and impacts of structural mutations in the human genome, with particular emphasis on how these alterations affect gene function in developmental contexts and drive cancer progression. His group studies complex structural rearrangements in challenging cancer types including ovarian cancer, glioblastoma, and mesothelioma, where tumor genomes undergo dramatic reorganization. The research is guided by four key questions: What are the origins of structural mutations? How do they impact gene function? How does structural complexity drive disease progression? How do diverse mutational constellations combine to create adaptations and vulnerabilities? Analysis of Professor Semple's publications reveals a consistent focus on structural variation in cancer genomics, with particular attention to ovarian cancer mechanisms, lesion segregation in tumor evolution, and the functional consequences of genomic rearrangements. His work frequently employs whole genome sequencing approaches to uncover previously hidden layers of genomic variation that affect more of the genome than traditional short variants. Professor Semple leads a substantial research team including bioinformaticians and PhD students, and oversees the Bioinformatics Analysis Core which provides collaborative expertise to over 500 researchers at the IGC. His group maintains strong collaborations with both local researchers at the University of Edinburgh and international consortia, working closely with clinicians to translate genomic findings into potential diagnostic and therapeutic approaches. The Semple Lab is funded by major organizations including the Medical Research Council (MRC), Cancer Research UK (CRUK), and the Chief Scientist Office (CSO).

• Cancer genomics
• Structural mutations
• Molecular evolution
• +5 more